Featured Story | By Annalee Armstrong Gilead revealed that a partial clinical hold for its CD47 targeted cancer hopeful is larger than originally thought. Disclosed in the fine print of the pharma giant’s fourth-quarter earnings presentation Tuesday was that two more studies are subject to the hold, bringing the total number of affected trials to seven. read more |
| |
|---|
|
Top Stories By Kyle LaHucik Pfizer's new development leader is on the way from Roche. Replacing 35-year Pfizer veteran Rod MacKenzie, Ph.D., as chief development officer will be William Pao, M.D., Ph.D. read more By Nick Paul Taylor Strike Novartis from the list of rivals to Incyte’s topical eczema drug Opzelura. After getting a look at early clinical data, Novartis has dumped its topical pan-JAK inhibitor CEE321 over an unfavorable risk-benefit profile. read more Sponsored by: TD2 Dive into the unique history of TD2 and learn how their approach to cancer drug development impacts clinical and partner success. read more By Kyle LaHucik President Joe Biden unveiled his second attempt at a "cancer moonshot" with a renewed program focused on slashing the cancer death rate by more than 50% in the next 25 years. read more Sponsored by: Precision for Medicine Advances in cancer biomarker discovery, validation and clinical applications hinge on one critical resource: Quality biospecimens. Optimize and accelerate program success by sourcing and selecting the right samples. read more By Nick Paul Taylor LogicBio Therapeutics’ bid to develop a genome editing therapy in infants has hit more trouble. Months after the first infant to receive the therapy suffered a serious adverse event, LogicBio has revealed the second subject has experienced the same clinical syndrome, prompting the FDA to impose a clinical hold. read more By Andrea Park Thin is in for AliveCor: The personal electrocardiogram tech maker scored FDA clearance for its slimmest heart monitor yet, which is the size and shape of a credit card and is aptly named the KardiaMobile Card. read more By Dave Muoio New Los Angeles County public health surveillance data reaffirm vaccines and boosters' protection against COVID-19, and particularly against severe illness. read more By Kevin Dunleavy The omicron variant has fueled a surge in demand for Gilead's Veklury, the company said on Tuesday when it reported fourth quarter and 2021 sales. The COVID-19 antiviral treatment rang up 2021 sales to $5.6 billion. The company is projecting Veklury to generate $2 billion in revenue in 2022. read more By Fraiser Kansteiner Blue Cross and Blue Shield of Minnesota has settled a class-action lawsuit against Martin Shkreli, his former company and another ex-CEO for $28 million, the insurance system said this week. The news comes after a federal judge ordered the "pharma bro" to pay nearly $65 million in disgorgement and exit the pharma industry for life. read more By Conor Hale The high-stakes transplant procedure set a new record for the company’s LUNGguard system, pushing past its intended organ storage time of up to eight hours. read more By Rebecca Torrence Fertility startup Kindbody hit a $1.15 billion valuation with its acquisition of Vios Fertility Institute, a deal that gives the company 13 more clinics, doubling its national footprint. read more Resources Sponsored by: Blue Matter, strategic consultants in the life sciences What’s in store for the CNS therapeutics market in 2022? This paper looks ahead in Alzheimer’s, Parkinson’s, DMD, psychiatric disorders, pain, and more. Sponsored by: Thermo Fisher Scientific Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Fierce Drug Safety Summit March 8-9, 2022 | Virtual Fierce BD&L Summit for Life Sciences March 15-16, 2022 | San Francisco, CA Fierce Medical Affairs Strategic Summit (MASS) East April 12-14, 2022 | New Brunswick, NJ Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Leaders in Life Sciences Forum May 16-17, 2022 | Virtual Event Fierce Health IT Summit May 24, 2022 | Virtual Event Fierce Digital Pharma: Engage June 14-15, 2022 | Huntington Beach, CA Fierce Pharma PR & Communications Summit West June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Biotech Next-Gen Week June 29-30, 2022 | Virtual Event Fierce Pharma PR & Communications Summit July 2022 | Location TBD (NYC Metro Area) Fierce MedTech Summit August 8-9, 2022 | Minneapolis, MN Fierce Diversity, Equity & Inclusion Forum August 15, 2022 | Virtual Event Fierce Biotech Summit October 10-11, 2022 | Location TBD Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Pharma Marketing Awards October 19, 2022 | Philadelphia, PA Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Fierce European Trial Master File Summit October 31- November 2, 2022 | London Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce New Product Planning Summit November 30 - December 1, 2022 | Boston, MA Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Boston, MA Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 
